schizophrenia. Schizophrenia
Conditions
Interventions
Intervention 1: Tablet Risperidone (2-6 mg/day) combined with 100 mg/day of Tablets Riluzole as intervention group for 8 weeks. Intervention 2: Tablets Risperidone (2-6 mg/day) combined with Tablets p
Treatment - Drugs
Placebo
Tablet Risperidone (2-6 mg/day) combined with 100 mg/day of Tablets Riluzole as intervention group for 8 weeks
Tablets Risperidone (2-6 mg/day) combined with Tablets placebo as control group for 8 weeks
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria:1- Age between 18-50, 2- Diagnosis of Schizophrenia based on DSM IV 3- chronic Schizophrenia( the duration of the disorder> 2 years), Minimum Score of 60 on Positive and Negative Scale- Exclusion Criteria:1- Substance dependence,2- IQ <70,3-any other mental disorder on axis I, 4-Any serious medical or neurological problem ,5- receiving oral antipsychotic medications during the last week or receiving any depot antipsychotic medication during the last month,6- receiving ECT during the last 14 days,7- hepatic disease
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in the severity of negative symptoms. Timepoint: Baseline and weeks 2, 4, 6 and 8 after begining of treatment. Method of measurement: Positive and Negative Syndrome Scale (PANSS). | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in other PANSS subscale scores. Timepoint: Weeks: 2, 4, 6 and 8. Method of measurement: Positive and Negative Syndrome Scale (PANSS). | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed